The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 5, 2015, Pages 605-615

  Gostner, Johanna M ^a   Becker, Kathrin ^a   Überall, Florian ^a   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anti inflammatory; Antiproliferative; GTP cyclohydrolase; Immunosuppressive; Indoleamine 2,3 dioxygenase; Kynurenine; Neopterin; Tolerance; Tryptophan; Tumor

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIOXIDANT; CHLOROQUINE; CYCLOSPORIN A; IMIDAZOLE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; METHYLPREDNISOLONE; PLANT MEDICINAL PRODUCT; RAPAMYCIN; TACROLIMUS; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE;

AMINO ACID BLOOD LEVEL; ANEMIA; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER TISSUE; CELLULAR IMMUNITY; DEPRESSION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; TRYPTOPHAN METABOLISM; TUMOR IMMUNITY; WEIGHT REDUCTION; ANIMAL; BLOOD; CELL PROLIFERATION; DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; METABOLISM; NEOPLASMS; PROCEDURES; T LYMPHOCYTE;

ANIMALS; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; KYNURENINE; NEOPLASMS; T-LYMPHOCYTES; TRYPTOPHAN;

EID: 84928499088     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.995092     Document Type: Review

References (113)

1. Schrocksnadel K, Wirleitner B,Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006;364:82-90
2. Thomas SR, Stocker R. Antioxidant activities and redox regulation of interferon-gamma-induced tryptophan metabolism in human monocytes and macrophages. Adv Exp Med Biol 1999;467:541-52
3. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013;34:137-43
4. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006;18:220-5
5. Brandacher G, Winkler C, Schroecksnadel K, et al. Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr Drug Metab 2006;7:599-612
6. Sucher R, Kurz K, Weiss G, et al. IDO-mediated tryptophan degradation in the pathogenesis of malignant tumor disease. Int J Tryptophan Res 2010;3:113-20
7. Yamazaki F, Kuroiwa T, Takikawa O, Kido R. Human indolylamine 2,3- dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochem J 1985;230:635-8
8. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007;396:203-13
9. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res 2009;2:1-19
10. Werner ER, Bitterlich G, Fuchs D, et al. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci 1987;41:273-80
11. Werner-Felmayer G, Werner ER, Fuchs D, et al. Tumour necrosis factoralpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler 1989;370:1063-9
12. Byrne GI, Lehmann LK, Kirschbaum JG, et al. Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res 1986;6:389-96
13. Kudo Y, Boyd CA, Spyropoulou I, et al. Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta. J Reprod Immunol 2004;61:87-98
14. Yoshida R, Imanishi J, Oku T, et al. Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc Natl Acad Sci USA 1981;78:129-32
15. Ball HJ, Yuasa HJ, Austin CJ, et al. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 2009;41:467-71
16. Pantouris G, Serys M, Yuasa HJ, et al. Human indoleamine 2,3-dioxygenase- 2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1. Amino Acids 2014;46:2155-63
17. Lob S, Konigsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009;58:153-7
18. Metz R, Smith C, DuHadaway JB, et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a nonredundant function in inflammation. Int Immunol 2014;26:357-67
19. Merlo LM, Pigott E, DuHadaway JB, et al. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J Immunol 2014;192:2082-90
20. Knox WE. The regulation of tryptophan pyrrolase activity by tryptophan. Adv Enzyme Regul 1966;4:287-97
21. Knox WE, Piras MM, Tokuyama K. Induction of tryptophan pyrrolase in rat liver by physiological amounts of hydrocortisone and secreted glucocorticoids. Enzymol Biol Clin (Basel) 1966;7:1-10
22. Wolf H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest Suppl 1974;136:1-186
23. Sainio EL, Pulkki K, Young SN. Ltryptophan: biochemical, nutritional and pharmacological aspects. Amino Acids 1996;10:21-47
24. Weissbach H, King W, Sjoerdsma A, Udenfriend S. Formation of indole-3-acetic acid and tryptamine in animals: a method for estimation of indole-3-acetic acid in tissues. J Biol Chem 1959;234:81-6
25. Dai W, Pan H, Kwok O, Dubey JP. Human indoleamine 2,3-dioxygenase inhibits toxoplasma gondii growth in fibroblast cells. J Interferon Res 1994;14:313-17
26. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991;5:2516-22
27. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferongamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983;158:670-89
28. Werner ER, Werner-Felmayer G, Fuchs D, et al. Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem J 1989;262:861-6
29. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002;3:175-87
30. Werner ER, Werner-Felmayer G, Fuchs D, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T 24 cells. GTP-cyclohydrolase I is stimulated by interferon-gamma, and 6- pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem 1990;265:3189-92
31. Schneemann M, Schoedon G, Hofer S, et al. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J Infect Dis 1993;167:1358-63
32. Haara A, Geisler S, Becker K, et al. Comparison of ELISA and HPLC assays to determine blood kynurenine concentrations in men and mice. Pteridines 2014;25:19
33. Gostner JM, Becker K, Fuchs D, Sucher R. Redox regulation of the immune response. Redox Rep 2013;18:88-94
34. Schroecksnadel K, Fischer B, Schennach H, et al. Antioxidants suppress Th1-type immune response in vitro. Drug Metab Lett 2007;1:166-71
35. Jenny M, Klieber M, Zaknun D, et al. In vitro testing for anti-inflammatory properties of compounds employing peripheral blood mononuclear cells freshly isolated from healthy donors. Inflamm Res 2011;60:127-35
36. Gostner J, Ciardi C, Becker K, et al. Immunoregulatory impact of food antioxidants. Curr Pharm Des 2014;20:840-9
37. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-3
38. Widner B, Werner ER, Schennach H, Fuchs D. An HPLC method to determine tryptophan and kynurenine in serum simultaneously. Adv Exp Med Biol 1999;467:827-32
39. Fuchs D, Moller AA, Reibnegger G, et al. Increased endogenous interferongamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett 1991;28:207-11
40. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002;3:175-87
41. Weinlich G, Murr C, Richardsen L, et al. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 2007;214:8-14
42. Giusti RM, Maloney EM, Hanchard B, et al. Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type Iassociated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/ lymphoma. Cancer Epidemiol Biomarkers Prev 1996;5:699-704
43. Schroecksnadel K, Winkler C, Fuith LC, Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 2005;223:323-9
44. Huang A, Fuchs D, Widner B, et al. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691-6
45. Denz H, Orth B, Weiss G, et al. Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin Investig 1993;71:37-41
46. Munn DH. Indoleamine 2,3- dioxygenase, Tregs and cancer. Curr Med Chem 2011;18:2240-6
47. Fallarino F, Grohmann U. Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. Curr Med Chem 2011;18:2215-21
48. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17- like T cells. J Immunol 2009;183:2475-83
49. Mayer E, Holzl M, Ahmadi S, et al. CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk. Int Immunopharmacol 2013;15:638-45
50. Mellor AL, Chandler P, Baban B, Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004;16:1391-401
51. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51
52. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002;9:1069-77
53. Lee SM, Lee YS, Choi JH, Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion. Immunol Lett 2010;132:53-60
54. Hayashi T, Mo JH, Gong X, et al. 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc Natl Acad Sci USA 2007;104:18619-24
55. Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008;453:65-71
56. Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008;453:106-9
57. Mezrich JD, Fechner JH, Zhang X, An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010;185:3190-8
58. Bessede A, Gargaro M, Pallotta MT, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 2014;511:184-90
59. Grallert B, Boye E. The Gcn2 kinase as a cell cycle regulator. Cell Cycle 2007;6:2768-72
60. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3- dioxygenase. Immunity 2005;22:633-42
61. Tsalikis J, Croitoru DO, Philpott DJ, Girardin SE. Nutrient sensing and metabolic stress pathways in innate immunity. Cell Microbiol 2013;15:1632-41
62. Murguia JR, Serrano R. New functions of protein kinase Gcn2 in yeast and mammals. IUBMB Life 2012;64:971-4
63. Ye J, Kumanova M, Hart LS, et al. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J 2010;29:2082-96
64. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74
65. Choe JY, Yun JY, Jeon YK, et al. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer 2014;14:335
66. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011;17:6985-91
67. Brody JR, Costantino CL, Berger AC, et al. Expression of indoleamine 2,3- dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009;8:1930-4
68. Chamuleau ME, van de Loosdrecht AA, Hess CJ, et al. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 2008;93:1894-8
69. Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006;95:1555-61
70. Urakawa H, Nishida Y, Nakashima H, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 2009;26:1005-12
71. Pan K, Wang H, Chen MS, et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008;134:1247-53
72. Riesenberg R, Weiler C, Spring O, et al. Expression of indoleamine 2,3- dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 2007;13:6993-7002
73. Jacquemier J, Bertucci F, Finetti P, et al. High expression of indoleamine 2,3- dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 2012;130:96-104
74. Litzenburger UM, Opitz CA, Sahm F, et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget 2014;5:1038-51
75. Platten M, Litzenburger U, Wick W. The aryl hydrocarbon receptor in tumor immunity. Oncoimmunology 2012;1:396-7
76. Opitz CA, Litzenburger UM, Sahm F. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478:197-203
77. Pilotte L, Larrieu P, Stroobant V, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3- dioxygenase. Proc Natl Acad Sci USA 2012;109:2497-502
78. Batabyal D, Yeh SR. Human tryptophan dioxygenase: a comparison to indoleamine 2,3-dioxygenase. J Am Chem Soc 2007;129:15690-701
79. Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 1988;263:2041-8
80. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009;121:29-40
81. Fiaschi T, Chiarugi P. Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int J Cell Biol 2012;2012:762825
82. Theofylaktopoulou D, Ulvik A, Midttun Ø, et al. Vitamins B2 and B6 as determinants of kynurenines and related markers of interferon-g-mediated immune activation in the communitybased Hordaland Health Study. Br J Nutr 2014;112:1065-72
83. Linkswiler H. Biochemical and physiological changes in vitamin B6 deficiency. Am J Clin Nutr 1967;20:547-61
84. Rose DP. Aspects of tryptophan metabolism in health and disease: a review. J Clin Pathol 1972;25:17-25
85. Chung KT, Gadupudi GS. Possible roles of excess tryptophan metabolites in cancer. Environ Mol Mutagen 2011;52:81-104
86. Walczak K, Dabrowski W, Langner E, et al. Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scand J Gastroenterol 2011;46:903-12
87. Walczak K, Zurawska M, Kis J, et al. Kynurenic acid in human renal cell carcinoma: its antiproliferative and antimigrative action on Caki-2 cells. Amino Acids 2012;43:1663-70
88. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumorinfiltrating T cells. Clin Cancer Res 2006;12:1144-51
89. Weiss G, Schroecksnadel K, Mattle V, et al. Possible role of cytokine-induced tryptophan degradation in anaemia of inflammation. Eur J Haematol 2004;72:130-4
90. Kurz K, Gluhcheva Y, Zvetkova E, et al. Interferon-gamma-mediated pathways are induced in human CD34(+) haematopoietic stem cells. Immunobiology 2010;215:452-7
91. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-21
92. Jones SP, Guillemin GJ, Brew BJ. The kynurenine pathway in stem cell biology. Int J Tryptophan Res 2013;6:57-66
93. Denz H, Orth B, Weiss G, et al. Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin Investig 1993;71:37-41
94. Kurz K, Schroecksnadel S, Weiss G, Fuchs D. Association between increased tryptophan degradation and depression in cancer patients. Curr Opin Clin Nutr Metab Care 2011;14:49-56
95. Sperner-Unterweger B, Kohl C, Fuchs D. Immune changes and neurotransmitters: possible interactions in depression? Prog Neuropsychopharmacol Biol Psychiatry 2014;48:268-76
96. Dantzer R, Heijnen CJ, Kavelaars A, et al. The neuroimmune basis of fatigue. Trends Neurosci 2014;37:39-46
97. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012;37:137-62
98. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003;17(Suppl 1):S119-24
99. Widner B, Laich A, Sperner-Unterweger B, et al. Neopterin production, tryptophan degradation, and mental depression - what is the link? Brain Behav Immun 2002;16:590-5
100. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012;13:465-77
101. Fukui S, Schwarcz R, Rapoport SI, et al. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991;56:2007-17
102. Rohrig UF, Awad L, Grosdidier A, et al. Rational design of indoleamine 2,3- dioxygenase inhibitors. J Med Chem 2010;53:1172-89
103. Di PT, Danese S, De CR, Rutella S. Inhibitors of indoleamine 2,3- dioxygenase: a review of novel patented lead compounds. Expert Opin Ther Pat 2010;20:229-50
104. Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. OncoImmunology 2014;3:1-10
105. Dolusic E, Frederick R. Indoleamine 2,3- dioxygenase inhibitors: a patent review (2008-2012). Expert Opin Ther Pat 2013;23:1367-81
106. Dolusić E, Larrieu P, Moineaux L, et al. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem 2011;54:5320-34
107. Pantouris G, Mowat CG. Antitumour agents as inhibitors of tryptophan 2,3- dioxygenase. Biochem Biophys Res Commun 2014;443:28-31
108. Schroecksnadel S, Sucher R, Kurz K, et al. Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells. Transpl Immunol 2011;25:119-23
109. Schroecksnadel K, Winkler C, Wirleitner B, et al. Aspirin downregulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro. Clin Exp Immunol 2005;140:41-5
110. Gostner JM, Schrocksnadel S, Becker K, et al. Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC. FEBS Open Bio 2012;2:241-5
111. Schroecksnadel S, Gostner J, Jenny M, et al. Immunomodulatory effects in vitro of vitamin K antagonist acenocoumarol. Thromb Res 2013;131:e264-9
112. Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 2000;70:690-4
113. Fuchs D, Malkovsky M, Reibnegger G, et al. Endogenous release of interferongamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol Lett 1989;23:103-8